soul trial oral semaglutide cardiovascular outcomes results 2025 Reduces CV Events in T2DM β (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine π§ͺ T2DM + ASCVD/CKD π Oral semaglutide 14 mg vs placebo π SOUL Trial Shows Oral Semaglutide
Description
Clinical trials advance treatments and care so people with type 1 diabetes (T1D) can live fuller, healthier lives
Weight Loss Timeline: When Results Appear on the Scale Actual weight loss typically becomes measurable around week 4-6 of semaglutide treatment, though some patients see changes by week 2-3
In conclusion, ED represents a common yet frequently underrecognized microvascular complication of diabetes, influenced by a broad spectrum of risk factors
Retatrutide is triple acting, hitting GLP-1, GIP, and glucagon receptors
doi: 10.3390/nu15184072
While licensed by the MHRA, NICE recommends semaglutide for weight management only within specialist weight management services and under more restricted BMI criteria than the licence
